I do think they will now shop this around to BP -
Post# of 147665
Not only did they not hold back the early observations, they threw some shade at Resmiterom in Point #3 when they said, “Leronlimab monotherapy (700 mg) appears to have better anti-fibrotic activity compared to Resmetirom (p=0.057).”
They used the word “appears” because the p value is not less than 0.05, and they didn’t want to upset the FDA, but I think Ohm is right, that a larger mouse study would probably bring that p value to less than 0.05.
I loved points 1) and 2) but 3 gave me a confident chuckle